Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
|
|
PDS Biotechnology Corp (EDGE)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 10/11/2023 |
8-K
| Quarterly results |
| 10/03/2023 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
| 10/03/2023 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
| 10/03/2023 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
| 10/02/2023 |
8-K
| Quarterly results |
| 08/18/2023 |
8-K
| Quarterly results |
| 08/17/2023 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data|
Docs:
|
"Abstract #: 55593 Abstract Title: HPV Circulating Cell-Free DNA Kinetics in Cervical Cancer Patients Undergoing Definitive Chemoradiation Presenter: Aaron Seo Author Block: Aaron Seo, Weihong Xiao, Olsi Gjyshi, Kyoko Court, Tatiana Cisneros Napravnik, Aradhana Venkatesan, Erica Lynn, Julie Sammouri, Lauren Colbert, Anuja Jhingran, Melissa Joyner, Lilie Lin, Maura Gillison, Ann Klopp Scientific Session Number: SS 02 Scientific Session Title: GYN 1: Integrating the Next Wave of Biomarkers for Future Gynecologic Clinical Trials Session Date/Time: October 1, 8:00AM-9:00AM" |
|
| 08/14/2023 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
| 08/14/2023 |
8-K
| Quarterly results |
| 08/14/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 07/25/2023 |
8-K
| Quarterly results |
| 07/17/2023 |
4
| Freitag Gregory Gene (Director) has filed a Form 4 on PDS Biotechnology Corp|
Txns:
| Granted 9,000 options to buy
@ $5.13, valued at
$46.2k
|
|
| 07/17/2023 |
4
| BRAWLEY OTIS W (Director) has filed a Form 4 on PDS Biotechnology Corp|
Txns:
| Granted 9,000 options to buy
@ $5.13, valued at
$46.2k
|
|
| 07/17/2023 |
4
| Ali-Jackson Kamil (Director) has filed a Form 4 on PDS Biotechnology Corp|
Txns:
| Granted 9,000 options to buy
@ $5.13, valued at
$46.2k
|
|
| 07/17/2023 |
4
| SYKES RICHARD (Director) has filed a Form 4 on PDS Biotechnology Corp|
Txns:
| Granted 9,000 options to buy
@ $5.13, valued at
$46.2k
|
|
| 07/17/2023 |
4
| Glover Stephen C. (Director) has filed a Form 4 on PDS Biotechnology Corp|
Txns:
| Granted 9,000 options to buy
@ $5.13, valued at
$46.2k
|
|
| 07/17/2023 |
4
| Iliev Ilian (Director) has filed a Form 4 on PDS Biotechnology Corp|
Txns:
| Granted 9,000 options to buy
@ $5.13, valued at
$46.2k
|
|
| 07/17/2023 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data|
Docs:
|
"Abstract Title: Combining an IL-12-based Immunocytokine with Docetaxel in Metastatic Prostate Cancer: Preliminary Safety and Immune Data Paper Number: 249 Presenting Author: Head, Prostate Cancer Clinical Research Section, Ravi A. Madan Authors: Renee Donahue, Yo-Ting Tsai, Mohammad O. Atiq, Elias Chandran, Luke Meininger, Fatima Karzai, Marijo Bilusic, Jennifer Marte, Philip M. Arlen, Lisa Cordes, Megan Hausler, Amy Hankin, Nikki Williams, William D. Figg, Jeff Schlom, James L. Gulley, Ravi A. Madan Session Details: Plenary 3: Cytokines in Cancer Immunity and Immunotherapy, Mittwoch; Olympia A+B Session Date and Time: October 18, 2023, 10:00-10:15 For patients interested in enrolling in this clinical trial, please contact NCI’s toll-free number 1-800-4-Cancer and/or the Web site: https:/..." |
|
| 07/17/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 07/11/2023 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
| 06/01/2023 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
| 05/25/2023 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
| 05/25/2023 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
| 05/18/2023 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
| 05/17/2023 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
| 05/15/2023 |
8-K
| Quarterly results |
| 04/28/2023 |
10-K/A
| Annual Report for the period ended December 31, 2022 [amend] |
| 04/27/2023 |
8-K
| Quarterly results |
| 04/27/2023 |
8-K
| Quarterly results |
| 04/24/2023 |
8-K
| Quarterly results |
| 04/21/2023 |
8-K
| Quarterly results |
| 04/06/2023 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
| 03/28/2023 |
10-K
| Annual Report for the period ended December 31, 2022 |
| 03/28/2023 |
8-K
| Quarterly results |
|
|
|